In addition, most of the broadly validated cancer biomarkers are biofluidic glycoproteins, including but not limited to alpha-fetoprotein (AFP), CA19-9 (cancer antigen 19-9), CA125, CA15-3, carcinoembryonic antigen (CEA), and prostate-specific antigen (PSA) [211]. This evidence concerns the gene CEACAM5 and cancer.